Anti-clotting drug rivaroxaban wins FDA panel's support

03/19/2009 | NYTimes.com

A panel of FDA advisers endorsed the approval of rivaroxaban, an anti-coagulant by Johnson & Johnson and Bayer Healthcare Pharmaceuticals, as a preventive treatment for deep-vein thrombosis and pulmonary embolism in patients undergoing total knee- or hip-replacement surgery. The product could become an alternative to blockbuster drug warfarin if it gains final FDA clearance.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC